OurInsightsTitle

Our extensive experience in health technology
assessment (HTA) through providing strategic
advice and guiding evidence generation to
support submissions to UK HTA bodies, enables
us to provide you with a tailored solution to
reimbursement and patient access.

Real-World Comparator Evidence for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: Derivation of an NHS England Registry Cohort to Support Indirect Comparative Effectiveness Analyses.

Register to access the Tolley insights